Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

During the last three months, 21 analysts shared their evaluations of Biogen (NASDAQ:BIIB), revealing diverse outlooks from bullish to bearish. In the table below, you'll find a summary of their ...

In the latest quarter, 9 analysts provided ratings for Biogen (NASDAQ:BIIB), showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by ...

One of the healthier stocks on the market Friday was veteran biotech Biogen (NASDAQ: BIIB). The company unveiled its final set of fundamentals for 2025, and it crushed analyst estimates for both ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, ...

Biogen (NASDAQ:BIIB) outlined its growing “West Coast Hub” and development plans for felzartamab, an anti-CD38 antibody being studied across multiple kidney-related immunology indications, during a ...

Is Biogen (NASDAQ: BIIB) about to be acquired? One news article published on Wednesday reported that this is a possibility. As a result, the company's shares shot up almost 10% higher on the day. It ...

The biotech published its last set of financials for 2025. Its quarterly revenue and adjusted profitability declined, yet both still topped the consensus analyst estimates. One of the healthier stocks ...